New senior VP, finance at Eli Lilly
pharmafile | August 10, 2016 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Eli Lilly
Eli Lilly has announced that Joshua Smiley is set to become senior vice president, finance, and treasurer from October 1, replacing Thomas Grein who is set to retire after a 41-year career at the company.
Smile currently serves as senior vice president, finance, and controller and chief financial officer for Lilly Research Laboratories. In his new role, he will report to Derica Rice, executive vice president, global services, and chief financial officer.
Rice says: “Josh’s knowledge and skill helped to place Lilly in a position of strength. Josh is a strong analytical and strategic thinker who excels at distilling complex business matters into clear thoughts and actions.”
Smiley has spent 21 years with Lilly, in a range of financial, marketing and Six Sigma roles.
His current role will be taken by Anat Ashkenazi who currently serves as chief financial officer for Lilly Manufacturing, Global Quality and Lilly Diabetes. Rice comments: “Anat has a very effective ability to apply strategy into practical solutions. Her exposure to many parts of our organisation – including R&D, manufacturing and commercial – combined with her learning agility, energy and commitment, position Anat well for her new role.”
Rice also paid tribute to the retiring Grein, after four decades at Lilly. He added: “[Grein] has been a steadfast pillar of leadership in our financial organisation. With Tom’s guidance, we maintained a strong balance sheet and cash flow that enabled us to make acquisitions and sustain our dividend commitment to Lilly shareholders, even when times were tough.”
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
